Symposia: Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Biological therapies, Antibody Therapy, Clinical Practice (Health Services and Quality), Lymphomas, Non-Biological therapies, Chemotherapy, Diseases, indolent lymphoma, Therapies, Lymphoid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Biological therapies, Antibody Therapy, Clinical Practice (Health Services and Quality), Lymphomas, Non-Biological therapies, Chemotherapy, Diseases, indolent lymphoma, Therapies, Lymphoid Malignancies
Monday, December 11, 2023: 4:30 PM-6:00 PM
Grand Hall C
(Manchester Grand Hyatt San Diego)
Moderators:
Wojciech Jurczak, MD, PhD, MSC National Research Institute of Oncology
and
Rahul Lakhotia, MBBS, National Cancer Institute, National Institutes of Health
Disclosures:
Jurczak: Abbvie, Astra Zeneca, Bayer, BeiGene, Celtrion, Celgene, Debbiopharm, Epizyme, Incyte, Janssen, Loxo Oncology, Merck, Mei Pharma, Morphosys, Novo Nordisk, Roche, Sandoz, Takeda, TG Therapeutics: Research Funding; Astra Zeneca, BeiGene, Janssen, Loxo Oncology, Sandoz, Roche: Consultancy.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH